



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number:

**0 642 798 A2**

(12)

## EUROPEAN PATENT APPLICATION

23

(21) Application number: 93309720.6

(51) Int. Cl. 5: **A61K 47/48**

(22) Date of filing: 03.12.93

(20) Priority: 08.09.93 US 118055  
22.10.93 US 142598  
15.11.93 US 152506  
22.11.93 EP 93309288

(43) Date of publication of application:  
15.03.95 Bulletin 95/11

(94) Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IE IT LI LU NL  
PT SE

(71) Applicant: **LA JOLLA PHARMACEUTICAL  
COMPANY**  
6455 Nancy Ridge Drive, Suite 300  
San Diego, California 92121 (CA)

(72) Inventor: **Coutts, Stephen**  
6151 Rancho Diegueno Road  
Rancho Santa Fe, CA 92067 (US)  
Inventor: **Jones, David S.**  
11265 Florindo Road  
San Diego, CA 92127 (US)  
Inventor: **Livingston, Douglas Alan**  
5260 Fiore Terrace, No.115  
San Diego, CA 92122 (US)  
Inventor: **Yu, Lin**  
8933 Lombard Place, Apt. 228  
San Diego, CA 92122 (US)

(74) Representative: **Goldin, Douglas Michael et al**  
**J.A. KEMP & CO.**  
14, South Square  
Gray's Inn  
London WC1R 5LX (GB)

(54) **Chemically-defined non-polymeric valency platform molecules and conjugates thereof.**

(57) Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies.

EP 0 642 798 A2